Study on the effect of liraglutide as an adjunct therapy in regulating metabolic disorders in obese patients with newly diagnosed type 2 diabete

ZENG Hai-yong; LI Hai-yan; CHEN Shu-juan; LIU Xue-ting; WANG Xin-yun; CHEN Ze-long; LIU Ming-ming; LYU Ling-bo; YAN De-wen

doi:10.13820/j.cnki.gdyx.20240731

Abstract：Objective To investigate the efficacy of liraglutide as an adjunct therapy in regulating metabolic dis-orders in obese patients with newly diagnosed type 2 diabetes.Methods This prospective study selected 116 patients di-agnosed with newly onset type 2 diabetes and obesity due to metabolic disorders from April 2022 to April 2023.Patients were divided into four groups based on their medication regimen:Metformin-1 group,Metformin-2 group,Empaglifloz-in-1 group,and Empagliflozin-2 group.The Metformin-1 and Empagliflozin-1 groups received monotherapy with Metformin and Empagliflozin,respectively,while the Metformin-2 and Empagliflozin-2 groups received liraglutide in addition to their respective monotherapies over a 12-week treatment period.Changes in obesity indices[(body mass in-dex(BMI),waist circumference],glucose metabolism indices[fasting plasma glucose(FPG),2-hour postprandial glucose(2hPG),glycated hemoglobin(HbA1c)],lipid metabolism indices[high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC),triglycerides(TG)],insulin resistance index(HOMA-IR),pancreatic β-cell function index(HOMA-β),total adiponectin(tAPN),irisin,and serum se-creted frizzled-related protein 5(SFRP5)were observed.Adverse reactions were also recorded during treatment.Results At baseline(T0),there were no significant differences among the four groups regarding obesity indices,glucose metab-olism indices,lipid metabolism indices,HOMA-IR,HOMA-β,tAPN,irisin,and SFRP5(P＞0.05).Similarly,comparisons between Metformin-1 and Empagliflozin-1 groups at T1 showed no significant differences(P＞0.05).However,the improvements in T1 for obesity,glucose,and lipid metabolism indices,HOMA-IR,HOMA-β,tAPN,irisin,and SFRP5 were significantly more pronounced in the Metformin-2 and Empagliflozin-2 groups compared to their respective monotherapy groups(P＜0.05).The overall incidence of adverse reactions,including headache,dizziness,gastrointestinal reactions,urinary infections,and hypoglycemia,did not differ significantly among the groups(P＞0.05).Conclusion For obese patients with newly diagnosed type 2 diabetes,early health education and treatment with Metform-in or Empagliflozin are effective.The addition of liraglutide as an adjunct therapy significantly enhances metabolic im-provement and weight control without increasing adverse reactions,suggesting that liraglutide is a valuable adjunct treat-ment for metabolic disorders in these patients and can be promoted for clinical use.